Dualsystems has closed a Series C financing round with support from existing and new investors to implement and drive forward its new business strategy in mass spectrometry based protein interaction discovery

Dualsystems Biotech, a privately held biotech company based in Schlieren, Switzerland, today announces the closing of its Series C financing round.

Following the recently announced licensing of a new technology to provide mass-spectrometry based target- and protein-interaction discovery services from the ETH Zurich and the sale of its former yeast-based technologies business, the company now has successfully raised additional funds from existing and new investors.

"This is the third and consequential step in the transition process of Dualsystems Biotech during which we have moved from the previous yeast-based techniques towards a portfolio of highly innovative mass-spectrometry based services for target interaction discovery. These new services will be provided to the life sciences industry as well as to academic groups …" Dr. Andreas J. Schulze, CEO, says.

About Dualsystems Biotech AG

Dualsystems Biotech (www.dualsystems.com) is a Swiss biotech company founded in 2000. Dualsystems successfully introduced yeast 2-hybrid technologies to the market and has been the leader in broadening its fields of application. In recent years the mass spectrometry-based proteomics technologies have become a major pillar of the company's expertise. The company now exclusively focuses on its mass spectrometry-based CaptiVate and CaptiRec technologies.